SynthesisFrontiers in cellular and infection microbiology2025
Efficacy and safety of different drugs for the treatment of leishmaniasis: a systematic review and network meta-analysis.
Synthesis in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antileishmanial Activity of Bioactive Compounds Obtained fromMolecules (Basel, Switzerland) · 2026Pooled it
- In Silico Screening ofBiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Leishmaniasis is a vector-borne neglected tropical infectious disease hat can be fatal if visceral leishmaniasis is left untreated. At present, many drugs have been used to treat leishmaniasis. This study aims to compare the efficacy and safety of different drugs to treat leishmaniasis through a network meta-analysis. Methods: All studies were retrieved from PubMed, Embase, and Cochrane databases, and the search time was from the date of database establishment to February 21, 2024. We assessed rates of clinical cure, mortality, and adverse effects (diarrhea, vomiting, injection site pain, and liver-enzyme abnormalities). We performed subgroup analyses of rates of clinical cure according to geographic region. All statistical analyses were performed using R and STATA 14.0 software for network meta-analysis. PROSPERO registration number: CRD42023478585. Results: 12 articles with 2483 patients were included in this study, and the therapeutic effects of 5 drugs were evaluated. The results of the network Meta-analysis showed that the clinical cure rate of miltefosine, pentavalent antimony, and paromomycin was inferior to amphotericin B (RR 0.31; 95%CI 0.07-11.4, RR 0.23; 95%CI 0.04-1.39, RR 0.12; 95% CI 0.01-1.55), and amphotericin B may have the highest clinical cure rate. The mortality of pentavalent antimony was higher than that of amphotericin B and miltefosine (RR 4.81; 95%CI 0.42-41.45, RR 3.75; 95% CI 0.57-24.74), pentavalent antimony may be the drug with the highest mortality during treatment. About adverse effects, vomiting, and diarrhea were most common with miltefosine, and pain at the injection site and abnormalities in aspartate aminotransferase and alanine aminotransferase were most common with paromomycin. Subgroup analysis showed that clinical cure rates using Pentavalent antimony treatment were better in Brazil than in Ethiopia and India. Conclusions: This systematic review and network meta-analysis provide a new comparative framework for the clinical management of leishmaniasis. The results of network meta-analysis suggest that amphotericin B may be the first choice for the treatment of leishmaniasis, pentavalent antimony may be the drug with the highest mortality during treatment, miltefosine causes the highest incidence of gastrointestinal reactions, and paromomycin causes the highest incidence of injection site pain, aspartate aminotransferase, and alanine aminotransferase abnormalities. More high-quality studies are still needed to further determine the optimal drug for the clinical treatment of leishmaniasis in the future. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023478585.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.